argenx (NASDAQ:ARGX) had its target price raised by Piper Jaffray Companies from $161.00 to $182.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has an “overweight” rating on the stock. Piper Jaffray Companies’ target price would indicate a potential upside of 37.81% from the stock’s current price.

A number of other equities analysts have also weighed in on ARGX. Stifel Nicolaus reiterated a “buy” rating on shares of argenx in a report on Monday, February 4th. ValuEngine upgraded shares of argenx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Guggenheim started coverage on shares of argenx in a report on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. Wedbush boosted their price objective on shares of argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Finally, Zacks Investment Research lowered shares of argenx from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $147.55.

Shares of ARGX opened at $132.07 on Thursday. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of -56.20 and a beta of 1.12. argenx has a fifty-two week low of $63.81 and a fifty-two week high of $135.58.

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in shares of argenx by 1,715.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,429 shares of the company’s stock valued at $1,170,000 after acquiring an additional 14,579 shares in the last quarter. We Are One Seven LLC acquired a new position in shares of argenx during the 4th quarter valued at $27,000. Fosun International Ltd acquired a new position in shares of argenx during the 4th quarter valued at $3,109,000. TD Asset Management Inc. lifted its holdings in shares of argenx by 7.5% during the 4th quarter. TD Asset Management Inc. now owns 49,978 shares of the company’s stock valued at $4,801,000 after acquiring an additional 3,500 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in shares of argenx by 31.3% during the 4th quarter. New York State Common Retirement Fund now owns 75,820 shares of the company’s stock valued at $7,284,000 after acquiring an additional 18,079 shares in the last quarter. 65.68% of the stock is owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

See Also: What does cost of debt say about a company’s financial health?

The Fly

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.